Background:

• Genomic scars assay measured by SNP (single nucleotide polymorphisms)-based tests are increasingly used clinically to identify patients more likely to benefit from PARP inhibitors (PARPi) in ovarian cancer.
• We aim to leverage the extensive SNP coverage built into a WES platform to accurately measure genomic loss of heterozygosity (LOH) and homologous recombination deficiency (HRD).
• We assessed the validity of WES compared to the whole genome sequencing (WGS) in identifying LOH.
• HRD was correlated with clinical outcome in PARPi-treated ovarian cancer patients.